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Calcinosis Cutis Related to Sclerodermatous 
Chronic Graft Versus Host Disease
Gabriel H. Lipshutz, M.D., and Felix S. Chew, M.D. 
We present the case of a 54-year-old woman who had calcinosis cutis related to sclerodermatous 
chronic graft versus host disease. Graft versus host disease had developed following stem cell trans-
plantation for acute myelogenous leukemia 14 years earlier, but was shown by skin biopsy to have 
resolved by the time of presentation. Radiographs showed extensive cutaneous calcifications in the 
lower extremities.
Calcinosis cutis, or calcification of the skin, is a 
radiologic finding that is associated with a variety of 
conditions. We present a case of calcinosis cutis that 




A 54-year-old woman presented with bilateral foot 
pain. Fourteen years earlier, at age 40, she was treated 
for acute myelogenous leukemia by myeloablative 
peripheral stem cell transplant from her HLA-matched 
sister. Two years later, at age 42, she was diagnosed with 
GVHD involving multiple organs, including the joints, 
liver, mouth, vagina, eyes, lungs and skin. She was ini-
tially treated with prednisone and cyclosporine for im-
munosuppression, but these were discontinued within 
the year due to depression and adequate control of her 
GVHD. One year later, at age 43, she was noted to 
have a reprisal of her GVHD manifested by tightening 
and thickening of the skin over her arms, hands, legs, 
and feet. A diagnosis of sclerodermatous GVHD was 
confirmed by skin biopsy. Immunosuppressive therapy 
was re-started with tacrolimus. Cellcept was later added 
due to progression of her scleroderma with new onset of 
joint contractures. These medications were discontinued 
due to lack of subjective improvement and azathioprine 
was started at age 46. Azathioprine was discontinued 
three years later, at age 49, and subsequent skin biopsies 
have not shown evidence of GVHD, though her sclero-
dermatous skin changes have not resolved.
The patient stated that, over the past year, she had 
had pain in her feet from a progressive loss of the fat 
pads of her soles. She also noted a loss of fat in her 
calves and thighs. Review of her past medical history in-
cluded insulin dependent diabetes mellitus, neuropathy 
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Figure 1. 54-year-old woman with calcinosis cutis and scle-
rodermatous graft versus host disease. Radiographs of the 
right lower leg (A), left lower leg (B), and left hip (C) show 
calcifications in the skin (arrows), some of which overlie the 
bones. 
of the lower legs, diabetic nephropathy, hyperlipidemia, 
pericarditis, anxiety and depression.
Physical exam revealed persistent and severe tight-
ening and thickening of the skin over her lower legs, 
feet, and forearms that was essentially unchanged and 
in some places improved compared to physical exams 
performed over the past 4 years. There were multiple 
small sclerotic nodules in the calves bilaterally and left 
buttock. There was patchy hyperpigmentation and mild 
erythema of the upper medial arms and axillae. The 
rest of her physical exam was unremarkable. Her total 
Rodnan score was 17.75, which was improved from 
18.25 four years earlier. Her complete blood count 
was normal. Her calcium levels were normal at 9.9 and 
albumin was 3.8. Phosphate was low at 2.9. Sodium was 
136, potassium 4.6, chloride 100, bicarbonate 27, and 
blood urea nitrogen 25. Her creatinine was 0.9 which 
was at baseline for her. Radiographs showed diffuse cal-
cified nodules of the soft tissue overlying the right and 
left iliac spines as well as the proximal and distal lower 
legs (Fig. 1). Biopsies of the skin from her thigh, arm, 
and buttock were performed shortly after the current 
visit and showed fibrosis and calcifications, indicative of 
calcinosis cutis, but no evidence of active GVHD. 
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Calcinosis cutis is a condition characterized by calci-
um deposits in the dermis or hypodermis [1]. There are 
four types of calcinosis cutis based on etiology: dystro-
phic, metastatic, idiopathic, and iatrogenic. Dystrophic 
calcinosis cutis is the most common form and occurs 
in abnormal tissue with normal serum calcium and 
phosphate levels. The exact mechanism of calcification 
is unknown. Dystrophic calcinosis is associated with 
connective tissue disease such as systemic lupus erythe-
matosis, dermatomyositis, and systemic sclerosis as well 
as devitalized tissue from trauma or infection.
Metastatic calcinosis is characterized by elevated 
serum calcium and phosphorous levels in the presence 
of normal, undamaged tissue. Diseases associated with 
metastatic calcinosis include malignancy, hypervita-
minosis D, hyperparathyroidism, milk-alkali syndrome, 
paraneoplastic hypercalcemia, sarcoidosis, chronic renal 
failure, and destructive bone disease [2]. Idiopathic cal-
cinosis occurs in the setting of normal tissue and normal 
serum and phosphorous levels. This type of calcinosis 
has been observed in childhood disorders like Down 
syndrome, idiopathic calcinosis of the scrotum, and 
subepidermal calcified nodule of Winer [3]. Iatrogenic 
calcinosis typically occurs secondary to intravenous 
calcium chloride or calcium gluconate therapy for 
hypocalcemia [4].
There are a number of diseases that can affect the 
skin post allogenic bone marrow transplant. The most 
common is acute graft vs. host disease, which occurs 
in 50-80% of bone marrow transplant patients. The 
incidence of chronic graft vs. host disease, defined as 
GVHD that persists beyond or begins 40 days after 
bone marrow transplant, is 30-50%. Skin involvement 
in chronic GVHD is reported to occur 90-100% of 
the time [4]. Other common skin problems post-bone 
marrow transplant include infections related to immu-
nosuppression with bacteria, fungi, protozoa, or viruses 
such as human papilloma virus (molluscum contagio-
sum, and verruca vulgaris). Medication side effects can 
cause allergic rashes, skin pigmentation, and petechiae. 
Immunosupppressed patients are also at increased risk of 
malignancy [5].
The most common skin manifestations of acute 
GVHD include erythema, hyperpigmentation, and 
desquamation of the axillae and groin, which occurs 
in about 55% of patients who have acute GVHD with 
Discussion
skin involvement. Erythematous maculopapular erup-
tions occur in about 29% of these patients. Chronically, 
lichenoid GVHD is the most common skin lesion. It 
is characterized by plaques that are purple or violet in 
color, which can be difficult to differentiate from lichen 
planus. Sclerodermoid GVHD is characterized by skin 
sclerosis and fibrosis. It has been reported to occur in 
about 11% of allogenic bone marrow transplant patients 
at a median time of 15 months after transplant. While 
sclerodermatous GVHD shares many of the same 
features of systemic sclerosis, Raynaud’s phenomenon, 
calcinosis, and Scl-70 and anti-centromere antibodies 
are virtually always absent [6-7].
As mentioned above, dystrophic calcification is most 
commonly found in patients with rheumatic diseases, 
such as scleroderma, dermatomyositis, and systemic 
lupus erythematosus as well as tissue damaged by infec-
tion or trauma. Furthermore, it is often discovered 
incidentally and has a predilection for the extremities 
and buttocks. While the mechanism of dystrophic 
calcification is unknown, several theories have been 
postulated for its development, including an imbalance 
between promoters and inhibitors of calcium deposition 
as a result of high alkaline phosphatase or acid levels in 
devitalized tissue, the influx of calcium into cells with 
damaged cell membranes, the precipitation of calcium 
caused by phosphate bound to denatured proteins, high 
mitochondrial calcium and phosphate cytosolic levels, 
and local tissue ischemia from tissue damage or steroid 
use [8]. Although calcinosis cutis is well known to be as-
sociated with systemic sclerosis and CREST syndrome, 
our literature search failed to locate previous reports of 
calcinosis cutis related to GVHD. There is, however, 
one reported case of calcinosis cutis post allogenic bone 
marrow transplant [5]. In this case, skin biopsy demon-
strated no evidence of GVHD. In the absence of other 
identifiable causes of calcinosis, it was thought that 
the calcinosis was secondary to allogenic bone marrow 
transplant.
In the present case, normal calcium and only mildly 
decreased phosphorous levels make metastatic calcino-
sis unlikely. Moreover, while the patient had diabetic 
nephropathy with microalbuminuria, her baseline creati-
nine levels were within normal range and she showed 
no evidence of primary or secondary hyperparathyroid-
ism, though her parathyroid hormone levels were not 
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